Income Statement Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
120.40 ^USD	-2.28%		-0.68%	+30.35%

12-12	Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	CI
12-12	Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	DJ

42dc9ccb96dd6a2d.D7LQeb3eQk3dS-lo9VdhoM71ivIDxg0U5Wh8-xnmOMQ.XOeqI9G0CnmnD9A9kyYW856bsp9l8E93ul8_vk65SpBL-ukO2vMmJ5R42Q

Published financial data: GILEAD SCIENCES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	24.69B	27.3B	27.28B	27.12B	28.75B
Total Revenues	24.69B	27.3B	27.28B	27.12B	28.75B
Cost of Goods Sold, Total	3.69B	5.53B	5.66B	6.02B	6.25B
Gross Profit	21B	21.78B	21.62B	21.1B	22.5B
Selling General & Admin Expenses, Total	4.91B	5.25B	5.67B	5.54B	6B
R&D Expenses	4.87B	5.36B	4.98B	5.76B	5.82B
Other Operating Expenses, Total	9.78B	10.61B	10.65B	11.3B	11.82B
Operating Income	11.22B	11.17B	10.97B	9.8B	10.69B
Interest Expense, Total	-984M	-1B	-935M	-944M	-977M
Interest And Investment Income	-	-	-	376M	281M
Net Interest Expenses	-984M	-1B	-935M	-568M	-696M
Currency Exchange Gains (Loss)	-51M	21M	-21M	-21M	14M
Other Non Operating Income (Expenses)	295M	-50M	97M	11M	-15M
EBT, Excl. Unusual Items	10.48B	10.14B	10.12B	9.22B	9.99B
Restructuring Charges	-	-	-	-527M	-189M
Merger & Related Restructuring Charges	-1.29B	-	-	-	-
Gain (Loss) On Sale Of Investments	-1.66B	-610M	-657M	-167M	-274M
Asset Writedown	-	-	-	-	-
In Process R&D Expenses	-5.86B	-177M	-3.64B	-1.2B	-8.84B
Legal Settlements	-	-1.08B	-	-525M	-
Other Unusual Items	-	-	-	60M	7M
EBT, Incl. Unusual Items	1.67B	8.28B	5.81B	6.86B	691M
Income Tax Expense	1.58B	2.08B	1.25B	1.25B	211M
Earnings From Continuing Operations	89M	6.2B	4.57B	5.61B	480M
Net Income to Company	89M	6.2B	4.57B	5.61B	480M
Minority Interest	34M	24M	26M	52M	-
Net Income - (IS)	123M	6.22B	4.59B	5.66B	480M
Net Income to Common Incl Extra Items	123M	6.22B	4.59B	5.66B	480M
Net Income to Common Excl. Extra Items	123M	6.22B	4.59B	5.66B	480M
Per Share Items
Net EPS - Basic	0.1	4.96	3.66	4.54	0.38
Basic EPS - Continuing Operations	0.1	4.96	3.66	4.54	0.38
Basic Weighted Average Shares Outstanding	1.26B	1.26B	1.26B	1.25B	1.25B
Net EPS - Diluted	0.1	4.93	3.64	4.5	0.38
Diluted EPS - Continuing Operations	0.1	4.93	3.64	4.5	0.38
Diluted Weighted Average Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B
Normalized Basic EPS	5.24	5.06	5.06	4.66	5.01
Normalized Diluted EPS	5.21	5.04	5.03	4.62	4.98
Dividend Per Share	2.72	2.84	2.92	3	3.08
Payout Ratio	2.8K	57.91	80.77	67.24	816.25
Supplemental Items
EBITDA	12.7B	13.22B	13.08B	12.5B	13.45B
EBITA	12.41B	12.89B	12.75B	12.14B	13.07B
EBIT	11.22B	11.17B	10.97B	9.8B	10.69B
EBITDAR	12.87B	13.38B	13.24B	12.66B	13.62B
Total Revenues (As Reported)	24.69B	27.3B	27.28B	27.12B	28.75B
Effective Tax Rate - (Ratio)	94.67	25.09	21.47	18.18	30.54
Current Domestic Taxes	1.65B	2B	2.57B	1.86B	1.53B
Current Foreign Taxes	155M	185M	232M	381M	519M
Total Current Taxes	1.8B	2.19B	2.8B	2.24B	2.05B
Deferred Domestic Taxes	-261M	-65M	-1.66B	-956M	-1.95B
Deferred Foreign Taxes	38M	-47M	101M	-39M	106M
Total Deferred Taxes	-223M	-112M	-1.56B	-995M	-1.84B
Normalized Net Income	6.58B	6.36B	6.35B	5.82B	6.24B
Interest on Long-Term Debt	994M	1B	940M	-	-
Supplemental Operating Expense Items
Advertising Expense	795M	735M	778M	826M	869M
Selling and Marketing Expenses	795M	735M	778M	826M	869M
Research And Development Expense From Footnotes	10.9B	5.54B	8.62B	6.92B	14.75B
Net Rental Expense, Total	171M	156M	162M	165M	163M
Imputed Operating Lease Interest Expense	46.87M	42.06M	45.65M	48.42M	48.09M
Imputed Operating Lease Depreciation	124M	114M	116M	117M	115M
Stock-Based Comp., COGS (Total)	109M	40M	46M	57M	61M
Stock-Based Comp., R&D Exp. (Total)	462M	287M	285M	377M	458M
Stock-Based Comp., SG&A Exp. (Total)	505M	308M	313M	361M	450M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	1.08B	635M	644M	795M	969M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	6B	5.34B	5.41B	6.08B	9.99B
Short Term Investments	2.62B	2.63B	1.45B	2.26B	1.58B
Total Cash And Short Term Investments	8.61B	7.96B	6.86B	8.35B	11.57B
Accounts Receivable, Total	4.89B	4.49B	4.78B	4.66B	4.42B
Other Receivables	9M	-	-	-	-
Total Receivables	4.9B	4.49B	4.78B	4.66B	4.42B
Inventory	1.68B	1.62B	1.51B	1.79B	1.71B
Prepaid Expenses	788M	622M	1.24B	1.28B	480M
Deferred Tax Assets Current	-	-	-	-	-
Other Current Assets, Total	12M	75M	60M	7M	995M
Total Current Assets	16B	14.77B	14.44B	16.08B	19.17B
Gross Property Plant And Equipment	7.28B	7.56B	8.17B	8.35B	8.4B
Accumulated Depreciation	-1.67B	-1.89B	-2.19B	-2.45B	-2.47B
Net Property Plant And Equipment	5.61B	5.66B	5.98B	5.9B	5.93B
Long-term Investments	2.26B	2.84B	2.61B	2.16B	327M
Goodwill	8.11B	8.33B	8.31B	8.31B	8.31B
Other Intangibles, Total	33.13B	33.46B	28.89B	26.45B	19.95B
Deferred Tax Assets Long-Term	-	-	-	-	-
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	3.31B	2.89B	2.93B	3.22B	5.3B
Total Assets	68.41B	67.95B	63.17B	62.12B	59B
Liabilities
Accounts Payable, Total	844M	705M	905M	550M	833M
Accrued Expenses, Total	6.39B	7B	6.53B	5B	5.12B
Short-term Borrowings	-	-	-	-	-
Current Portion of Long-Term Debt	2.76B	1.52B	2.27B	1.8B	1.82B
Current Portion of Leases	107M	101M	111M	125M	113M
Current Income Taxes Payable	598M	539M	959M	1.21B	1.65B
Unearned Revenue Current, Total	-	-	-	-	-
Other Current Liabilities	701M	1.75B	455M	2.6B	2.48B
Total Current Liabilities	11.4B	11.61B	11.24B	11.28B	12B
Long-Term Debt	28.64B	25.18B	22.96B	23.19B	24.9B
Long-Term Leases	608M	489M	467M	546M	498M
Deferred Tax Liability Non Current	-	4.36B	2.67B	1.59B	724M
Other Non Current Liabilities	9.54B	5.25B	4.63B	2.77B	1.63B
Total Liabilities	50.19B	46.89B	41.96B	39.38B	39.75B
Common Stock, Total	1M	1M	1M	1M	1M
Additional Paid In Capital	3.88B	4.66B	5.55B	6.5B	7.7B
Retained Earnings	14.38B	16.32B	15.69B	16.3B	11.5B
Comprehensive Income and Other	-60M	83M	2M	28M	132M
Total Common Equity	18.2B	21.07B	21.24B	22.83B	19.33B
Minority Interest	19M	-5M	-31M	-84M	-84M
Total Equity	18.22B	21.06B	21.21B	22.75B	19.25B
Total Liabilities And Equity	68.41B	67.95B	63.17B	62.12B	59B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.26B	1.25B	1.25B	1.25B	1.25B
ECS Total Common Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B
Book Value / Share	14.52	16.8	17.03	18.33	15.51
Tangible Book Value	-23.03B	-20.72B	-15.97B	-11.94B	-8.93B
Tangible Book Value Per Share	-18.37	-16.52	-12.81	-9.58	-7.17
Total Debt	32.12B	27.28B	25.81B	25.66B	27.32B
Net Debt	23B	18.01B	17.7B	16.14B	15.75B
Debt Equivalent Oper. Leases	1.37B	1.25B	1.3B	1.32B	1.3B
Minority Interest, Total (Incl. Fin. Div)	19M	-5M	-31M	-84M	-84M
Equity Method Investments, Total	-	338M	-	-	-
Account Code - Inventory Valuation	5	5	5	5	5
Land - (BS)	404M	404M	562M	561M	561M
Buildings, Total	3.68B	3.79B	4.39B	4.33B	4.54B
Machinery, Total	1.7B	1.76B	1.99B	2.22B	2.28B
Full Time Employees	13.6K	14.4K	17K	18K	17.6K
Accumulated Allowance for Doubtful Accounts (Supple)	44M	47M	55M	56M	52M

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	123M	6.22B	4.59B	5.66B	480M
Depreciation & Amortization - CF	288M	329M	323M	354M	381M
Amortization of Goodwill and Intangible Assets - (CF)	1.19B	1.72B	1.78B	2.34B	2.39B
Depreciation & Amortization, Total	1.48B	2.05B	2.1B	2.69B	2.77B
(Gain) Loss on Sale of Investments - (CF)	1.66B	610M	657M	167M	274M
Asset Writedown & Restructuring Costs	5.86B	177M	3.64B	1.2B	8.84B
Stock-Based Compensation (CF)	643M	635M	637M	766M	835M
Tax Benefit from Stock Options	-	-	-	-	-
Other Operating Activities, Total	42M	1.2B	-798M	-187M	-1.49B
Change In Accounts Receivable	-1.17B	313M	-406M	157M	139M
Change In Inventories	-195M	11M	-310M	-842M	-426M
Change In Accounts Payable	80M	-118M	226M	-347M	290M
Change in Unearned Revenues	-	-	-	-	-
Change In Income Taxes	-778M	-364M	-568M	-1.77B	-732M
Change in Other Net Operating Assets	426M	647M	-705M	497M	-151M
Cash from Operations	8.17B	11.38B	9.07B	8.01B	10.83B
Capital Expenditure	-650M	-579M	-728M	-585M	-523M
Cash Acquisitions	-25.74B	-1.4B	-1.8B	-1.15B	-4.84B
Investment in Marketable and Equity Securities, Total	11.95B	-987M	60M	-528M	1.86B
Other Investing Activities, Total	-171M	-163M	-1M	0	58M
Cash from Investing	-14.62B	-3.13B	-2.47B	-2.26B	-3.45B
Long-Term Debt Issued, Total	8.18B	-	-	1.98B	3.46B
Total Debt Issued	8.18B	-	-	1.98B	3.46B
Long-Term Debt Repaid, Total	-2.5B	-4.75B	-1.5B	-2.25B	-1.97B
Total Debt Repaid	-2.5B	-4.75B	-1.5B	-2.25B	-1.97B
Issuance of Common Stock	256M	169M	309M	232M	422M
Repurchase of Common Stock	-1.58B	-546M	-1.4B	-1B	-1.15B
Common Dividends Paid	-3.45B	-3.6B	-3.71B	-3.81B	-3.92B
Common & Preferred Stock Dividends Paid	-3.45B	-3.6B	-3.71B	-3.81B	-3.92B
Other Financing Activities, Total	-138M	-145M	-173M	-278M	-281M
Cash from Financing	770M	-8.88B	-6.47B	-5.12B	-3.43B
Foreign Exchange Rate Adjustments	43M	-35M	-63M	57M	-40M
Net Change in Cash	-5.63B	-659M	74M	673M	3.91B
Supplemental Items
Cash Interest Paid	951M	979M	907M	891M	951M
Cash Income Tax Paid (Refund)	2.64B	2.51B	3.14B	3.99B	2.78B
Levered Free Cash Flow	7.91B	10.29B	6.94B	8.79B	10.13B
Unlevered Free Cash Flow	8.53B	10.91B	7.52B	9.38B	10.74B
Change In Net Working Capital	387M	-1.82B	1.36B	-354M	-849M
Net Debt Issued / Repaid	5.68B	-4.75B	-1.5B	-270M	1.49B

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	10.78	10.24	10.46	9.78	11.03
Return on Total Capital	14.26	14.15	14.38	12.84	14.07
Return On Equity %	0.44	31.57	21.6	25.54	2.29
Return on Common Equity	0.6	31.7	21.71	25.71	2.28
Margin Analysis
Gross Profit Margin %	85.05	79.76	79.26	77.8	78.26
SG&A Margin	19.88	19.21	20.79	20.42	20.87
EBITDA Margin %	51.43	48.42	47.93	46.08	46.79
EBITA Margin %	50.26	47.21	46.75	44.77	45.46
EBIT Margin %	45.43	40.91	40.23	36.15	37.17
Income From Continuing Operations Margin %	0.36	22.71	16.74	20.7	1.67
Net Income Margin %	0.5	22.8	16.83	20.89	1.67
Net Avail. For Common Margin %	0.5	22.8	16.83	20.89	1.67
Normalized Net Income Margin	26.66	23.3	23.27	21.45	21.71
Levered Free Cash Flow Margin	32.06	37.67	25.42	32.43	35.23
Unlevered Free Cash Flow Margin	34.55	39.96	27.56	34.6	37.36
Asset Turnover
Asset Turnover	0.38	0.4	0.42	0.43	0.47
Fixed Assets Turnover	4.58	4.84	4.69	4.57	4.86
Receivables Turnover (Average Receivables)	5.83	5.82	5.89	5.75	6.33
Inventory Turnover (Average Inventory)	2.83	3.35	3.62	3.65	3.58
Short Term Liquidity
Current Ratio	1.4	1.27	1.29	1.43	1.6
Quick Ratio	1.19	1.07	1.04	1.15	1.33
Operating Cash Flow to Current Liabilities	0.72	0.98	0.81	0.71	0.9
Days Sales Outstanding (Average Receivables)	62.81	62.73	62.01	63.51	57.79
Days Outstanding Inventory (Average Inventory)	129.16	109.02	100.82	99.88	102.38
Average Days Payable Outstanding	64	51.77	52.98	42.16	40.99
Cash Conversion Cycle (Average Days)	127.97	119.98	109.85	121.23	119.17
Long Term Solvency
Total Debt/Equity	176.26	129.53	121.68	112.79	141.96
Total Debt / Total Capital	63.8	56.43	54.89	53	58.67
LT Debt/Equity	160.55	121.86	110.44	104.33	131.94
Long-Term Debt / Total Capital	58.11	53.09	49.82	49.03	54.53
Total Liabilities / Total Assets	73.36	69	66.43	63.38	67.38
EBIT / Interest Expense	11.4	11.16	11.74	10.38	10.94
EBITDA / Interest Expense	13.08	13.36	14.16	13.41	13.94
(EBITDA - Capex) / Interest Expense	12.42	12.78	13.38	12.79	13.4
Total Debt / EBITDA	2.5	2.04	1.95	2.03	2.01
Net Debt / EBITDA	1.79	1.35	1.34	1.28	1.16
Total Debt / (EBITDA - Capex)	2.63	2.13	2.06	2.12	2.09
Net Debt / (EBITDA - Capex)	1.88	1.41	1.42	1.34	1.2
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	9.98	10.6	-0.09	-0.6	6.04
Gross Profit, 1 Yr. Growth %	18.14	3.72	-0.71	-2.44	6.66
EBITDA, 1 Yr. Growth %	18.2	4.12	-6.47	-4.3	12.4
EBITA, 1 Yr. Growth %	18.33	3.88	-6.58	-4.65	12.54
EBIT, 1 Yr. Growth %	20.12	-0.42	-8.03	-10.51	15.2
Earnings From Cont. Operations, 1 Yr. Growth %	-98.34	6.87K	-26.37	22.93	-91.45
Net Income, 1 Yr. Growth %	-97.72	4.96K	-26.23	23.37	-91.53
Normalized Net Income, 1 Yr. Growth %	16.95	-3.35	-7.16	-8.17	13.75
Diluted EPS Before Extra, 1 Yr. Growth %	-97.68	4.94K	-26.17	23.63	-91.56
Accounts Receivable, 1 Yr. Growth %	36.57	-8.16	6.32	-2.45	-5.15
Inventory, 1 Yr. Growth %	82.54	-3.86	-6.86	18.58	-4.31
Net Property, Plant and Equip., 1 Yr. Growth %	8.57	0.89	5.6	-1.37	0.53
Total Assets, 1 Yr. Growth %	11	-0.67	-7.04	-1.66	-5.04
Tangible Book Value, 1 Yr. Growth %	-598.31	-10.05	-22.93	-25.26	-25.16
Common Equity, 1 Yr. Growth %	-19.19	15.75	0.81	7.5	-15.34
Cash From Operations, 1 Yr. Growth %	-10.67	39.37	-20.31	-11.75	35.25
Capital Expenditures, 1 Yr. Growth %	-21.21	-10.92	25.73	-19.64	-10.6
Levered Free Cash Flow, 1 Yr. Growth %	58.53	26.57	-32.03	27.03	19.68
Unlevered Free Cash Flow, 1 Yr. Growth %	51.93	24.82	-30.56	25	18.62
Dividend Per Share, 1 Yr. Growth %	7.94	4.41	2.82	2.74	2.67
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	5.63	10.29	5.12	-0.35	2.66
Gross Profit, 2 Yr. CAGR %	10.25	10.69	1.48	-1.58	2.01
EBITDA, 2 Yr. CAGR %	8.8	10.94	2.53	-5.47	1.43
EBITA, 2 Yr. CAGR %	8.71	10.87	2.45	-5.7	1.24
EBIT, 2 Yr. CAGR %	9.84	9.37	0.07	-9.36	-1.32
Earnings From Cont. Operations, 2 Yr. CAGR %	-87.23	7.52	616.26	-4.86	-67.58
Net Income, 2 Yr. CAGR %	-84.98	7.51	511.01	-4.6	-67.67
Normalized Net Income, 2 Yr. CAGR %	9.56	6.31	-0.57	-7.77	-0.82
Diluted EPS Before Extra, 2 Yr. CAGR %	-84.68	8.09	509.91	-4.46	-67.69
Accounts Receivable, 2 Yr. CAGR %	21.26	12	-1.18	1.84	-3.81
Inventory, 2 Yr. CAGR %	43.79	32.47	-5.37	5.09	6.52
Net Property, Plant and Equip., 2 Yr. CAGR %	18.37	4.66	3.22	2.05	-0.43
Total Assets, 2 Yr. CAGR %	3.65	5.01	-3.9	-4.38	-3.36
Tangible Book Value, 2 Yr. CAGR %	287.74	111.72	-16.74	-24.1	-25.21
Common Equity, 2 Yr. CAGR %	-7.75	-3.29	8.02	4.1	-4.6
Cash From Operations, 2 Yr. CAGR %	-1.39	11.58	5.39	-16.14	9.25
Capital Expenditures, 2 Yr. CAGR %	-16.13	-16.23	5.83	0.52	-15.24
Levered Free Cash Flow, 2 Yr. CAGR %	7.21	43.54	-6.69	-7.16	20.86
Unlevered Free Cash Flow, 2 Yr. CAGR %	6.22	39.41	-6.38	-6.91	19.52
Dividend Per Share, 2 Yr. CAGR %	9.22	6.16	3.61	2.78	2.7
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-1.84	7.26	6.71	3.17	1.74
Gross Profit, 3 Yr. CAGR %	-1.14	8.03	6.75	0.16	1.1
EBITDA, 3 Yr. CAGR %	-6.25	7.21	6.78	0.15	-1.28
EBITA, 3 Yr. CAGR %	-6.49	7.07	6.74	-0.03	-1.44
EBIT, 3 Yr. CAGR %	-7.39	6.31	5.53	-3.65	-3.61
Earnings From Cont. Operations, 3 Yr. CAGR %	-73.24	4.33	-5.23	298.05	-57.38
Net Income, 3 Yr. CAGR %	-70.16	4.5	-5.18	258.45	-57.44
Normalized Net Income, 3 Yr. CAGR %	-7.95	5.07	4.09	-3.24	-2.98
Diluted EPS Before Extra, 3 Yr. CAGR %	-69.68	5.74	-4.81	258.27	-57.44
Accounts Receivable, 3 Yr. CAGR %	8.3	10.53	10.07	-1.61	-0.54
Inventory, 3 Yr. CAGR %	28.08	25.73	17.8	2.02	1.86
Net Property, Plant and Equip., 3 Yr. CAGR %	19.43	12.23	4.97	1.66	1.54
Total Assets, 3 Yr. CAGR %	-0.9	2.19	0.83	-3.16	-4.6
Tangible Book Value, 3 Yr. CAGR %	204.35	138.25	51.17	-19.68	-24.46
Common Equity, 3 Yr. CAGR %	-3.79	-0.5	-1.94	7.85	-2.83
Cash From Operations, 3 Yr. CAGR %	-11.78	10.66	-0.26	-0.67	-1.66
Capital Expenditures, 3 Yr. CAGR %	3.28	-14.43	-4.08	-3.45	-3.33
Levered Free Cash Flow, 3 Yr. CAGR %	-9.06	14.31	11.58	3.35	-0.24
Unlevered Free Cash Flow, 3 Yr. CAGR %	-8.74	13.01	10.23	3.03	-0.27
Dividend Per Share, 3 Yr. CAGR %	9.35	7.6	5.03	3.32	2.74
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-5.43	-2.12	0.88	4.15	5.08
Gross Profit, 5 Yr. CAGR %	-6.01	-3.58	-0.1	4.08	4.83
EBITDA, 5 Yr. CAGR %	-11.43	-7.21	-3.23	3.1	4.61
EBITA, 5 Yr. CAGR %	-11.71	-7.51	-3.42	2.94	4.51
EBIT, 5 Yr. CAGR %	-12.76	-9.17	-4.92	1.06	2.74
Earnings From Cont. Operations, 5 Yr. CAGR %	-65.46	-14.39	-0.34	0.55	-38.29
Net Income, 5 Yr. CAGR %	-63.15	-14.34	-0.16	0.76	-38.34
Normalized Net Income, 5 Yr. CAGR %	-13.43	-10.32	-5.54	1.19	2.1
Diluted EPS Before Extra, 5 Yr. CAGR %	-61.72	-13.09	0.73	1.53	-38.21
Accounts Receivable, 5 Yr. CAGR %	-3.53	-0.09	4.4	6.97	4.29
Inventory, 5 Yr. CAGR %	-2.95	0.39	13.47	17.03	13.15
Net Property, Plant and Equip., 5 Yr. CAGR %	19.79	14.6	12.66	8.04	2.78
Total Assets, 5 Yr. CAGR %	5.75	3.59	-2.11	-0.49	-0.87
Tangible Book Value, 5 Yr. CAGR %	26.48	18.83	81.22	50.77	14.08
Common Equity, 5 Yr. CAGR %	-0.36	2.21	0.77	1.32	-3.01
Cash From Operations, 5 Yr. CAGR %	-17.41	-7.76	-5.28	-0.96	3.44
Capital Expenditures, 5 Yr. CAGR %	-2.74	-4.99	4.29	-8.74	-8.71
Levered Free Cash Flow, 5 Yr. CAGR %	-12.28	-6.31	-8	5.01	15.2
Unlevered Free Cash Flow, 5 Yr. CAGR %	-11.45	-5.98	-7.7	4.42	13.86
Dividend Per Share, 5 Yr. CAGR %	16.09	9.07	7.02	5.64	4.1